Tyra Biosciences Inc

Tyra Biosciences Inc has a strong liquidity position, with a current ratio of 14.67, indicating that the company holds significantly more current assets than current liabilities. The company's cash and equivalents amount to $77.39 million, which is a substantial portion of its total assets of $282.61 million. The company has no long-term debt, and its debt-to-equity ratio is 0.0, suggesting a conservative capital structure with no leverage. The company's profitability metrics are negative, with a return on equity (ROE) of -46.28% and a return on assets (ROA) of -42.44%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets to generate profit. The operating income is negative at -$132.76 million, and the net income is also negative at -$119.95 million, reflecting ongoing losses. Tyra Biosciences Inc operates in a single business segment, and its geographic exposure is not disclosed in the available data. The company's revenue concentration is not specified, but the absence of segment or geographic breakdown suggests that it may be focused on a single therapeutic area or market. The company's growth trajectory is not clearly defined in the available data, as there are no specific revenue growth figures provided. However, the company's operating cash flow is negative at -$95.14 million, and its free cash flow is also negative at -$119.54 million, indicating that the company is not generating positive cash flow from operations. The capital expenditure is relatively small at -$141,000, suggesting that the company is not heavily investing in new assets. The risk assessment for Tyra Biosciences Inc indicates low liquidity and dilution risks. The company has no immediate filing-based liquidity or dilution flags, and the dilution potential is assessed as low. The company's valuation is based on a price-to-book ratio of 8.64 and a price-to-tangible-book ratio of 8.64, which are relatively high, suggesting that the market is valuing the company's intangible assets at a premium. Recent events for Tyra Biosciences Inc include analyst estimates that suggest a positive outlook, with a mean price target of $50.40 and a median price target of $51.50. The mean recommendation from analysts is 1.50, which is a strong buy rating, with 7 strong-buy and 7 buy recommendations. These analyst estimates indicate that the market has a generally positive view of the company's future prospects.